Q-omics provides the consensus-scored CASP16P profile across patient tissues and cancer cell-line models. CASP16P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CASP16P is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, CASP16P RNA expression shows 18,623 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where CASP16P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASP16P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASP16P survival associations across molecular data types. CASP16P RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASP16P RNA expression–survival associations across cancer types. High CASP16P expression shows unfavorable associations in ACC, LUAD and CHOL, but favorable associations in KIRP, HNSC and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for CASP16P RNA expression.
This table summarizes CASP16P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CASP16P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASP16P shows lower tumor expression in THCA, COAD, KIRC and CHOL and higher tumor expression in KICH and BRCA. The THCA box plot shows higher CASP16P RNA expression in normal versus tumor tissue (log2 FC = −0.348, t-test p < 0.001).
This table shows molecular features associated with CASP16P in patient tissues and cancer cell lines. In patient samples, CASP16P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CASP16P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
